CareDx vs GeneDx
CDNA and WGS side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CDNA and WGS compare
CareDx is the larger company, worth 2.6 times as much as GeneDx ($4.1B against $1.5B).
CareDx grew revenue faster over the last twelve months (38.9% versus 14.6% for GeneDx).
CareDx keeps more of each dollar of sales as profit, with a net margin of 25.9% compared with −24.1% at GeneDx.
CareDx scores higher on the StockData Score (12 against 3 for GeneDx), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CDNA | WGS |
|---|---|---|
| Size and price | ||
| Market cap | $4.1B | $1.5B |
| Share price | $77.88 | $51.87 |
| Change, 1 year | 377% | −62.9% |
| Change, 5 years | 81.1% | −78.4% |
| Beta (5Y) | 1.51 | 1.99 |
| Employees | 765 | 1,300 |
| StockData Score | ||
| Total score | 12 (better) | 3 |
| Valuation score | 0 | 0 |
| Growth score | 2 (better) | 1 |
| Performance score | 4 (better) | 1 |
| Health score | 6 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 32.6× | – |
| P/S | 8.2× | 3.4× (better) |
| P/B | 8.8× | 6.3× (better) |
| EV/EBITDA | 28.6× | – |
| FCF yield | – | −6.5% |
| Fair value | $58.77 | $32.27 |
| Margin of safety | −32.5% (better) | −60.7% |
| Growth | ||
| Revenue growth (TTM) | 38.9% (better) | 14.6% |
| Revenue growth, 5Y average | 14.6% | 19.0% (better) |
| Net income growth (TTM) | 82.6% (better) | −5431% |
| EPS growth (TTM) | – | −6400% |
| Profitability | ||
| Gross margin | – | 68.7% |
| Operating margin | 23.4% (better) | −21.6% |
| Net margin | 25.9% (better) | −24.1% |
| FCF margin | – | −22.0% |
| Return on equity | 33.0% (better) | −41.4% |
| Return on invested capital | 69.8% (better) | −38.4% |
| Financial health | ||
| Debt / equity | 0.00 | 0.60 (better) |
| Current ratio | 2.31 | 4.16 (better) |
| Altman Z-score | 14.77 (better) | 0.16 |
| Piotroski F-score | 5 | 6 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 102% | 107% |
| Held by insiders | 4.8% | – |
| Insider net buying, 12 months | −$18.4M | $91.2M (better) |
| Short interest, % of float | 14.4% | – |
Go deeper
- CDNA stock overview
- CDNA income statement
- CDNA valuation and score
- WGS stock overview
- WGS income statement
- WGS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.